PSMA陽性mCRPCの成人患者を対象としたAAA817+ARPIと標準治療の比較研究

基本情報

NCT ID

NCT06855277

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

940

治験依頼者名

Novartis

概要

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or \[177Lu\]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.

対象疾患

介入

依頼者（Sponsor）